improvements in ankle pressures, CBF, and symptoms. 5 Moreover, the approach toward development of novel treatments, such as therapeutic angiogenesis, is Abstract: To the practicing clinician, it seems obvious that limb hemodynamics would be the primary determinant of walking distance. However, other determinants, such as skeletal muscle metabolism, may play a role. Accordingly, in the current study, we examined the relationship between measures of limb hemodynamics and walking capacity in patients with peripheral arterial disease (PAD). We measured toe and ankle pressures for calculation of toe-(TBI) and ankle (ABI)-brachial indices; basal and hyperemic calf blood flow (CBF; by plethysmography); and initial (ICT) and absolute (ACT) claudication time using the Skinner-Gardner protocol. As expected, PAD patients had impaired limb hemodynamics with reduced TBI, ABI and a reduction in ABI post-exercise. However, there was no relationship between any of the hemodynamic variables (including ABI, ABI reduction post-exercise, TBI, baseline or maximal CBF) and walking distance as assessed by ICT or ACT. A subset of PAD patients with an ACT Ͼ750 s (n ϭ 16; 'long claudicators') were compared with a subset of PAD patients with an ACT Ͻ260 s (n ϭ 16; 'short claudicators'). The average ACT in the long claudicants was over fivefold greater than the short claudicators. Surprisingly, there were no differences between the two groups in any of the hemodynamic variables. There was also no relationship between the initial ABI, TBI, toe pressure, baseline or hyperemic CBF, and the improvement in ACT over the 3-month course of the study. This study found little relationship between hemodynamic variables and functional capacity in PAD. Accordingly, to assess the response to therapeutic interventions, exercise performance and functional status need to be directly measured, and cannot be predicted from hemodynamic measurements.
Introduction
The symptoms of peripheral arterial disease (PAD) are typically associated with obstructive atherosclerotic plaque of the limb arteries. Hemodynamically significant lesions increase the resistance to blood flow, and cause a drop in pressure across the limb. In mild to moderate PAD, the obstructive lesions limit the increase in blood flow during exercise. As a result, the increased metabolic demand of the exercising muscle outstrips the blood supply, resulting in muscle ischemia. Exercise-induced muscle ischemia causes the classic symptom of intermittent claudication. To relieve the pain, the patient rests, reducing the metabolic demand. The ischemia and pain subside, as the limited blood flow gradually restores metabolic homeostasis. 1-3. Therefore, to the practicing clinician, it seems obvious that limb hemodynamics would be the primary determinant of walking distance. Indeed, patients with peripheral arterial disease typically manifest abnormal segmental pressure measurements and reduced ankle-brachial indices. With exercise, the ankle pressure falls in a patient with PAD. In addition, measurements of calf blood flow (CBF) are typically abnormal. 4 At rest, CBF may be normal in a patient with mild to moderate PAD, but hyperemic blood flow is significantly reduced. Furthermore, interventions to ameliorate or circumvent obstructive lesions (eg angioplasty or bypass surgery) are associated with based upon the conceptual framework that improvements in limb blood flow should result in improvements in walking distance. 6 However, there are data indicating that the correlation between limb hemodynamics and walking capacity in patients with PAD is surprisingly weak. 5, [7] [8] [9] [10] [11] In the current study, we examined the relationship between measures of limb hemodynamics and walking capacity in patients with PAD. In addition, we examined the predictive value of these hemodynamic measures by assessing the response to a therapeutic intervention. Our findings raise questions about a conceptual framework for new PAD therapies that is oriented exclusively on limb hemodynamics.
Methods
In the first cross-sectional study, we assessed which if any measurements of limb hemodynamics may be predictive of walking distance. In a second longitudinal study we assessed which if any measurements of limb hemodynamics may be predictive of an improvement in walking distance.
Sample
Subjects were recruited by newspaper advertisements targeting individuals with leg pain that limited the ability to walk. Respondents were then screened by telephone interview and eligible subjects were invited for further clinical assessment of their PAD and functional capacity. The final study sample consisted of 66 subjects with intermittent claudication due to PAD.
Eligibility criteria were: age Ͼ50 years; 6-month history of stable intermittent claudication due to PAD; ankle-brachial index (ABI) at rest of Ͻ0.90 (or in diabetic patients with calcified vessels a toe:brachial index of Ͻ0.60, or maximal hyperemic blood flow by strain gauge plethysmography Ͻ15 ml of blood/ 100 cc of tissue/minute); capacity to walk more than 2 minutes; no change in medications or physical activity within 3 months prior to enrollment.
Exclusion criteria included: peripheral vascular surgery, sympathectomy, peripheral angioplasty, or stent insertion within the previous 3 months; myocardial infarction (MI), unstable angina, percutaneous transluminal coronary angioplasty (PTCA), or coronary artery bypass graft surgery (CABG) within the previous 3 months; uncontrolled hypertension (resting SBP Ͼ190 or DBP Ͼ115 mmHg), symptomatic postural hypotension, or hypotension (SBP Ͻ90 mmHg); any other acute or chronic medical condition that in the opinion of the investigator increased the risk to the patient, or increased the likelihood that the patient would be unable to complete the longitudinal study; significant renal disease [any of the following: BUN Ͼ35 mg/dl, creatinine Ͼ2.0 mg/dl, proteinuria (defined as ϩϩ or greater on dipstick, and Ͼ250 mg/24 hour confirmed by a quantitative urinalysis of a 24-hour collection)]; liver disease (transaminase Ͼ3 ϫ upper limit of normal (ULN); bilirubin Ͼ1.5 ϫ ULN); a history of treatment for any malignancy within the past 5 years, or evidence of active malignancy other than squamous cell or basal cell carcinoma of the skin; or therapy with an investigational drug; or conditions other than PAD that limited walking distance.
Treadmill exercise test
Treadmill exercise tests were performed using a Skinner-Gardner graded exercise protocol 12 (Quinton Treadmill System Model 5000, Quinton Cardiology Systems Inc.) at the Stanford Medical Center. Initial claudication time (ICT) was recorded when the patient reported the onset of leg pain on the treadmill. Patients were then asked to walk until they were unable to walk further -and the absolute claudication time (ACT) was then recorded.
Treadmill tests were performed twice within a 2-week period. Treadmill tests were performed at least 24 hours apart. If the difference between the ACT obtained with the two treadmill tests was less than 25%, the patient was included in the study. If the variability was greater than 25%, a third treadmill test was performed at a separate visit. If the variability was more than 25%, the patient was excluded from participating in the study. Of the 66 patients enrolled into this study, the ACT was less than 12 minutes in 50 subjects, whereas 16 patients attained an ACT Ͼ12 minutes. Those patients exceeding the pre-specified ACT of 12 minutes were deemed 'long claudicators' for the purpose of further analysis.
Ankle-brachial index (ABI)
Systolic pressures were measured in all extremities at the brachial, dorsalis pedis and posterior tibial arteries using a pocket Doppler device (Elite Model No.100; Nicolet Vascular Inc.). All measurements were performed after 10 minutes of rest. The ABI for both legs were calculated as the ratio of the higher value of systolic pressure at the ankle and the higher systolic pressure obtained at the brachial arteries (according to SVMB guidelines). An ABI of the symptomatic (index) leg was used for further calculations.
Post-exercise ABI was measured in the index leg within 1 minute of completion of the treadmill exercise test. The difference between the resting ABI and post-exercise ABI was calculated to determine the post-exercise ABI drop. All measurements were performed at baseline and after completion of the longitudinal study.
Toe pressure and toe-brachial index Toe systolic pressures (toe pressure) were measured in the great toe of both feet using the Hokanson EC5R photoplethysmograph (Hokanson Inc.). The photoplethysmography probe was placed on the distal phalanx of the toe, and a small cuff was placed at the base of the toe. After the baseline pulse wave was recorded, the toe cuff was inflated above systolic pressure until the pulse wave deflections disappeared, and then was slowly deflated. Systolic pressure was recorded when the pulse wave reappeared. The toe pressure of the index leg was used for further calculations. Toe-brachial index (TBI) was calculated as the ratio of toe pressure of the index leg and the higher brachial pressure.
Mercury strain-gauge plethysmography CBF at rest (baseline calf flow, ie BCF) and after 5 minutes of induced calf ischemia (hyperemic or maximal calf flow, ie MCF) were measured using mercury-in-silastic strain-gauge plethysmography (EC5R plethysmograph; Hokanson Inc.). A venous occlusion cuff and an arterial occlusion cuff were placed around the thigh, and the appropriate strain gauge was placed around the calf at the largest circumference. A smaller foot exclusion cuff was placed above the ankle and inflated to suprasystolic pressure during the measurements. The measurements were made with the patient in the supine position after 10 minutes of rest. The index leg was slightly elevated, supported under the thigh and ankle. The largest calf circumference was measured and an appropriately sized strain gauge was placed around the calf. Serial recordings of limb blood flow were made during repetitive venous cuff occlusions. The baseline limb blood flow was calculated using the average of the first 5 consecutive measurements. Subsequently, a proximal arterial occlusion cuff was inflated. After five minutes of ischemia, the proximal arterial cuff was released. Maximal (hyperemic) blood flow was calculated using the first measurement immediately after release of the proximal arterial cuff.
Cross-sectional and longitudinal studies
The first study was a cross-sectional study of all 66 patients, to determine whether any measure of limb hemodynamics was predictive of ACT. The second study was a longitudinal study of the 50 patients with ACT Ͻ12 minutes to determine whether any measure of limb hemodynamics was predictive for a therapeutic response. The mean values for ICT and ACT were determined using the two qualifying visits (initial ICT and ACT) and two final visits (final ICT and ACT). The changes in values for ICT and ACT (ICT change, ACT change) were calculated subtracting an initial ICT (ACT) from a final ICT (ACT).
These patients (n ϭ 50) were a subset of the patients enrolled in the NO PAIN (Nitric Oxide for Peripheral Arterial INsufficiency, n ϭ 72) study, a 3-month, randomized, double-blind, dose ranging, placebocontrolled study of oral L-arginine in patients with PAD. The primary purpose of the NO PAIN study was to determine the lowest effective dose of oral L-arginine that would improve walking distance and quality of life in patients with PAD. The results of the NO PAIN dose-ranging study will be reported separately. This manuscript reports upon the correlation of limb hemodynamics with treadmill walking distance observed during the trial.
Statistics
Demographic and clinical characteristics of the study sample are reported as means and standard deviation. Associations between hemodynamic variables and walking distance were assessed using Pearson correlation coefficients. The α level for all tests was set at 0.05 using a two-tailed test of significance. For those variables that were statistically significant, a linear regression was calculated and the variability of the model was assessed. Differences between groups were examined using a one-way analysis of variance. Statistical analysis was performed using StatView 6.0 software.
Results

Cross-sectional study: Do hemodynamic variables predict functional capacity? Demographic and hemodynamic characteristics of claudicants
The demographic and baseline hemodynamic characteristics of our study population are shown in Tables 1  and 2 . As expected, PAD patients had an elevated cardiovascular risk (Table 1) , as well as evidence of impaired limb hemodynamics with reduced toe pressure, TBI, ABI and a reduction in ABI post-exercise (Table 2 ). There was no relationship between any of the hemodynamic variables (including ABI, ABI reduction post-exercise, TBI, baseline or maximal CBF) and walking distance as assessed by ICT or ACT ( Table 3 ; Figures 1 and 2 ).
Hemodynamic characterization of long distance versus short distance claudicants
A subset of PAD patients with an ACT Ͼ750 s (n ϭ 16) were compared with a subset of PAD patients (n ϭ 16) with an ACT Ͻ260 s. The average ACT in the short claudication group was 193 seconds. Using the Skinner-Gardner treadmill protocol, this translates into an absolute claudication distance of 172 m. Accordingly, most of the patients in this subset would be categorized as having Fontaine Class IIb PAD (ie ACT Ͻ200 m). The average ACT in the long claudicants was over fivefold greater at 1033 seconds (ie an absolute claudication distance of 930 m).
Surprisingly, there were no differences between the two groups in any of the hemodynamic variables.
The ABI values of the two groups were essentially identical, as were the TBI values (Table 4 ). There were no differences in the exercise-induced reduction in ABI. CBF under resting conditions, or with maximal hyperemia, was not different between the groups (Table 4 ).
Longitudinal study: do hemodynamic variables predict or correlate with improvement in walking distance over time? Do baseline limb hemodynamics predict change in walking distance?
The relationship between initial hemodynamic factors and the change in walking distance after a 3-month administration of the study drug was examined. Change in walking time was calculated as the difference between initial and final absolute walking time ( Table 5 ). There was no relationship between any of the hemodynamic variables at baseline and the improvement in initial claudication time change (ICT change). There was also no relationship between the initial ABI, TBI, toe pressure, baseline or hyperemic CBF, and the improvement in ACT ( Figure  3 , Table 5 ).
There was a weak (r ϭ 0.3) correlation between the baseline post-exercise ABI drop and the improvement in ACT over time (Table 5, Figure 4 ). Individuals with a greater post-exercise ABI drop after performance of an exercise treadmill test at the onset of the study experienced a larger improvement in walking distance by the completion of the study. 
Do changes in limb hemodynamics occur with changes in walking distance?
Changes in absolute walking distance over time generally were not accompanied by changes in hemodynamic variables over time in the study population (Table 6 ). Notably, improvements in walking distance were not associated with increases in CBF ( Figure 5 ). Indeed, there was no association between improvements in ACT and any changes in the hemodynamic variables of ABI. Furthermore, there was no association between improvements in ICT and ABI; toe pressure or TBI; hyperemic or baseline CBF. An improvement over time in ICT weakly correlated (r ϭ 0.34) with an improvement (reduction) in postexercise ABI drop over time ( Figure 6 ).
Limb hemodynamics in responders and non-responders
To test the hypothesis that directional changes over time in ACT are associated with similar directional changes in limb hemodynamics, we selected subjects who had improved the most during the 3-month trial ('responders') and those who had a negative response ('non-responders'; n ϭ 16 per group). There were no differences between these groups in the ACT or ICT at the beginning of the trial (Table 7) . Furthermore, there were no differences between these groups in their initial ABI or in any other measures of limb hemodynamics. Over the course of the study, the responders enjoyed a 61% improvement in ACT, whereas the nonresponders suffered a 19% decline. At the end of the study, there was a fivefold difference in ACT between responders and non-responders (Table 7) . By contrast, at the end of the study, there were no differences between the groups in any of the hemodynamic variables (Table 7 ).
Discussion
In cross-sectional and longitudinal studies, we found that limb hemodynamics are generally not correlated with, nor predictive of functional capacity in patients with PAD. Initial limb hemodynamics are not predictive of walking distance within a group of PAD patients. Furthermore, changes over time in walking distance are not correlated with changes in limb hemodynamics in patients with PAD. This investigation clearly shows that blood flow and blood pressure in the limb are not the sole determinants of functional capacity in patients with PAD. We extensively characterized a small population of subjects with PAD. Nevertheless, our findings are consistent with previous investigations indicating that intermittent claudication is a complex phenomenon that is only partially explained by insufficient blood supply to working muscles. To be sure, hemodynamically significant atherosclerosis is the initiating factor in the impaired functional capacity characteristic of PAD. Furthermore, interventions that increase limb blood flow improve functional capacity. However, there is a paucity of studies on limb hemodynamics and functional recovery post-procedure. It is not evident that any improvements in limb hemodynamics are directly correlated with functional improvements. Co-existing pathologies, not immediately or ever mitigated by surgical intervention, may significantly contribute to the impairment in functional capacity.
Furthermore, significant functional benefit can occur with little change in limb hemodynamics. Most notably, the benefits of a supervised exercise program are out of proportion with the modest improvement in CBF. A supervised exercise program for 12 weeks increased ACT by 123%, but maximal CBF only increased 38%. Moreover, there was no correlation between the improvement in CBF, and the improvement in walking distance. 13
Disease severity and walking distance
The relationship between disease severity as determined by ABI and walking distance is inconsistent at Table 4 for abbreviations.
Figure 5
The graph represents the correlation between change in an absolute walking distance on a treadmill (ACT change) and change in maximal (hyperemic) calf blood flow by plethysmography (MCF change). There is no significant correlation (r ϭ 0.04, p Ͼ 0.7). Indeed, many patients who improved their absolute walking distance on the treadmill had lower maximal calf blood flow after the study (shaded area). best. This variability may be explained by the use of different methods to assess walking distance. Whereas self-reported walking distance is reported to be associated with ABI 8, 14, 15 the correlations are weak. Feinglass and colleagues reported a very modest correlation (r Ͻ 0.2), while the correlation reported by Izquierdo-Porrera et al was better (r ϭ 0.3-0.4) in a highly selected group of veterans recruited for an exercise trial. 8, 14, 15 Other studies have shown that walking distance measured by treadmill testing is not highly correlated to the ABI. [16] [17] [18] [19] [20] [21] To determine whether baseline ABI might predict functional deterioration over time, McDermott and colleagues performed a prospective cohort study among 676 consecutively identified individuals with and without PAD (n ϭ 417 and n ϭ 259, respectively), with baseline functional assessments and follow-up assessments scheduled 1 and 2 years thereafter. 22 Although they found that longitudinal change was related to baseline ABI, this is due to the fact that subjects without PAD (ABI Ͼ 1.0) were being compared to patients with moderate or severe PAD. Additionally, limb blood flow at rest and during hyperemia using plethysmography was not associated with walking distance. Hyperemia should reflect changes in blood flow similar to that found with exercise. However, no correlation was observed in the current study between maximal CBF and maximal walking distance on a treadmill. This finding suggests that factors other than blood flow make a major contribution to the individual variability in walking distance.
Nevertheless, we did find that the decrease in postexercise ankle pressure was associated with walking distance. Furthermore, an improvement over time in the post-exercise ankle pressure drop correlated with improvement in walking distance. These observations suggest that a dynamic measure of pressure in the limb is superior to static measures of limb hemodynamics. Thus, the development of new technologies to assess dynamic measurements of limb pressure and flow during exercise may be a productive direction toward innovating tools to assess PAD and the effects of therapeutic interventions.
Certainly, there is need for new tools to quantify the alterations in limb hemodynamics in PAD, and their contribution to impaired functional capacity. This is because there are other determinants of functional capacity that are altered in PAD. Previous studies have found that chronic leg ischemia is associated with impaired muscle metabolism, 10,23-25 altered skeletal muscle phenotype, 26, 27 ischemic polyneuropathy, [28] [29] [30] including autonomic neuropathy, 30 autonomic flow dysregulations 31 and pathological flow redistribution with a possible blood shunting through non-nutritional circulation of working muscles. The latter is manifested by a loss of venoarteriolar response. 32 The presence of significant non-nutritional flow may also partially explain the relatively high hyperemic CBF in some of the subjects in this study. Other factors that may have an impact on walking distance include individual pain threshold and coexisting morbidities (psychiatric, neurological, musculoskeletal, rheological). 33 Additionally, walking pace is significantly different in the laboratory setting versus a free-living situation. However, at this time there are no protocols that allow subjects to control walking pace. 34 Little is known about the interaction of these factors in limiting Table 7 Hemodynamic variables in subjects who significantly improved their absolute walking distance on the treadmill ('Responders') had Ͼ100 s improvement in absolute walking distance; whereas subjects who shortened their walking distance during the NO PAIN study ('Non-responders') had a final ACT less than their initial ACT. walking distance, and further study is needed to understand the relationship of these variables to each other and to walking distance. Improved methods to evaluate these mechanisms, and to quantify their contribution to functional impairment would improve the tailoring of the individual therapeutic regimen, the design of clinical trials, and the evaluation of new therapies.
In summary, walking distance poorly correlates with limb hemodynamics. The only parameter that correlated with walking distance, and improvement over time, was the post-exercise reduction in ABI. Accordingly, to assess the response to therapeutic interventions, exercise performance and functional status need to be directly measured, and cannot be predicted from hemodynamic measurements. More accurate physiological and functional measures of disease severity and response to therapy are needed to improve the assessment of PAD.
